Almujtama Alraida Medical Co. vs Qomel Company
A head-to-head of Almujtama Alraida Medical Co. (9592) and Qomel Company (9600) across valuation, profitability, growth, and dividends. Green marks the more favourable value on that metric only — not a recommendation.
| Metric | 9592 | 9600 |
|---|---|---|
| Market Cap | 213.75M SAR | 343.14M SAR |
| P/E (TTM) | 25.18 | 22.46 |
| Forward P/E | — | — |
| P/S | — | 2.60 |
| P/B | 1.44 | 2.80 |
| EV/EBITDA | — | 17.95 |
| Dividend Yield | 111.00% | — |
| Profit Margin | 1.85% | 11.31% |
| Gross Margin | 32.93% | 30.03% |
| Operating Margin | 2.36% | 15.88% |
| Revenue Growth (YoY) | — | -7.10% |
| FCF Yield | — | — |
| Debt / Equity | — | 32.12 |
| Current Ratio | 1.07 | 2.31 |
Which is better: Almujtama Alraida Medical Co. or Qomel Company?
- ✓Larger by market cap: Qomel Company
- ✓Cheaper valuation (lower P/E): Qomel Company
- ✓More profitable (net margin): Qomel Company
Across 6 available metrics, Qomel Company leads 4–2.
There's no single "better" — it depends on your goal: income investors may prefer the higher yield, growth investors the faster grower, and value investors the cheaper one. See each stock's page for deeper detail. This is an automated read, not a recommendation.
Share:
Compare Almujtama Alraida Medical Co. with others
This comparison is for informational and educational purposes only, based on available data — not a recommendation to buy or sell any stock.